Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New blood test for ovarian cancer screening

Yale University : 09 May, 2005  (New Product)
A new blood screening test could help to identify ovarian cancer in its early stages when few symptoms are present, Yale School of Medicine researchers report in the May 10 issue of Proceedings of the National Academies of Sciences. Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the 'silent killer.'
A new blood screening test could help to identify ovarian cancer in its early stages when few symptoms are present, Yale School of Medicine researchers report in the May 10 issue of Proceedings of the National Academies of Sciences.

Epithelial ovarian cancer is the leading cause of gynecologic cancer deaths in the United States and three times more lethal than breast cancer. It is usually not diagnosed until its advanced stages and has come to be known as the 'silent killer.'

'Early diagnosis can help prolong or save lives, but clinicians currently have no sensitive screening method because the disease shows few symptoms,' said the study's lead author Gil Mor, M.D., associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine.

Mor conducted the research with David Ward, deputy director of the Nevada Cancer Institute. They developed and tested a new blood test for ovarian cancer based on four proteins: leptin, prolactin, osteopontin and insulin–like growth factor–II. If the level of two or more of these biomarkers for a patient falls within a certain warning area, the test will predict that she has cancer. In a test group of over 200 ovarian cancer patients and healthy women, the test showed 95 percent sensitivity (fraction correctly diagnosed with cancer) and 95 percent specificity (fraction correctly diagnosed as cancer–free).
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo